Somatostatin Analogs Market - Top Companies and Manufacturers

Companies Dominating the Somatostatin Analogs Landscape

Novartis AG
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
Sun Pharmaceutical Industries Ltd
Midatech Pharma PLC
Ipsen Pharma, Chiasma Inc.
Peptron, Inc
CRINETICS PHARMACEUTICALS
Dauntless Pharmaceuticals
Camurus AB
Pfizer Inc.

Browse Key Market Insights with Data Illustration:

Somatostatin Analogs Market Size & Share, Growth Forecasts 2036

In the News

Novartis AG announced that it has received a favorable opinion for Pluvicto a radioligand therapy, in combination with androgen deprivation therapy (ADT) for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC). Furthermore, the positive opinion is based on data from the Phase III VISION study, which would significantly improve overall survival in PSMA-positive mCRPC patients and provide transformative innovation to more patients around the world.
Sun Pharmaceutical Industries Ltd. teamed up with Philogen SpA for the commercialization of Nidlegy, a brand-new immunotherapy drug that Philogen is creating to treat both melanoma and non-melanoma skin cancers in New Zealand, Australia, and Europe.

Frequently Asked Questions (FAQ)

Rising prevalence of Cushing syndrome and the growing launch of advanced drug therapies for rare diseases are the major factors driving the growth of the market.

The market size of somatostatin analogs is anticipated to attain a CAGR of 8% over the forecast period, i.e., 2024-2036.

The major players in the market are Novartis AG, Sun Pharmaceutical Industries Ltd, Midatech Pharma PLC, Ipsen Pharma, Chiasma Inc., Peptron, Inc., CRINETICS PHARMACEUTICALS, Dauntless Pharmaceuticals, Camurus AB, Teva Pharmaceuticals Inc, and Pfizer Inc.

The octreotide segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.

The market in the North American region is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.

Somatostatin Analogs Market - Top Companies and Manufacturers

Companies Dominating the Somatostatin Analogs Landscape

Browse Key Market Insights with Data Illustration:

In the News

Frequently Asked Questions (FAQ)

What are the major factors driving the growth of the somatostatin analogs market?

What would be the CAGR of the somatostatin analogs market over the forecast period?

Who are the major players dominating the somatostatin analogs market?

Which segment captures the largest market size in the type segment in the somatostatin analogs market?

Which region will provide more business opportunities for the growth of the somatostatin analogs market in the future?